Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7539729 | 0.91 | EPHX2 (0.54) | L3MBTL1HTTTAAR1EPHX2EPHX1 | |
| SCHEMBL7380729 | 0.84 | ACE (0.49) | L3MBTL1HTTTAAR1EPHX2EPHX1 | |
| SCHEMBL27536629 | 0.84 | CPN1 (0.53) | L3MBTL1 | |
| SCHEMBL4288039 | 0.83 | L3MBTL1 (0.52) | L3MBTL1HTTTAAR1EPHX2EPHX1 | |
| SCHEMBL27495306 | 0.83 | CYP2C9 (0.61) | TAAR1EPHX2EPHX1CYP2C9CYP2C19 | |
| SCHEMBL31748828 | 0.81 | POLB (0.49) | HTTSMN1; SMN2CYP2C9CYP2C19HIF1A | |
| SCHEMBL4564333 | 0.78 | HTT (0.50) | L3MBTL1HTTTAAR1EPHX2EPHX1 | |
| SCHEMBL8638018 | 0.78 | CYP2C9 (0.55) | CYP2C9CYP2C19HIF1A | |
| SCHEMBL28382959 | 0.78 | TAAR1 (0.46) | HTTTAAR1EPHX2EPHX1NPC1 | |
| SCHEMBL7382520 | 0.78 | MME (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197879-B1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-26 | — | — | EP | disclosed |
| EP-3197879-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046390-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-03-31 | — | — | WO | disclosed |
| US-7301045-B2 | Method for preparing ester condensate | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2007-11-27 | — | — | US | disclosed |
| EP-1334960-B1 | METHOD FOR PREPARING ESTER CONDENSATE | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-20040015005-A1 | Process for producing esterificated condensate | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1334960-A1 | PROCESS FOR PRODUCING ESTERIFICATED CONDENSATE | Japan Science and Technology Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040015005-A1 | Process for producing esterificated condensate | HACL2, ADH5, ADH1C | L3MBTL1 4442/4885HTT 483/4885TAAR1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.